Crossmark

Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

Crossref DOI link: https://doi.org/10.1186/s12882-022-02930-4

Published Online: 2022-09-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Solis-Jimenez, Fabio

Perez-Navarro, Lucia Monserrat

Cabrera-Barron, Ricardo

Chida-Romero, Jesus Antonio

Martin-Alemañy, Geovana

Dehesa-López, Edgar

Madero, Magdalena

Valdez-Ortiz, Rafael
License Information

Text and Data Mining valid from 2022-09-20

Version of Record valid from 2022-09-20
More Information

Article History

Received: 10 May 2022

Accepted: 25 August 2022

First Online: 20 September 2022

Declarations

:

: All procedures were performed based on institutional guides in adherence to the principles of the Declaration of Helsinki and Title 45 of the US Code of Federal Regulations. The data analysis described in this paper is part of a larger ongoing study that has been submitted to and approved by both the Ethics and Research Committees of the Dr. Eduardo Liceaga Mexican General Hospital with the code DI/19/105B/03/018 prior to data collection. All participants read and signed an informed consent statement. The participants authorized to participate and publish the results. This trial was registered at clinicaltrials.gov, registry number NCT03923933.

: None of the authors have conflicts of interest to carry out this study.

Document is current

Any future updates will be listed below